As a pharmaceutical and healthcare company, STADA takes responsibility for the safety of its products and the well-being of patients. In our 2024 Sustainability Report, we outline our approach to sustainability, share our ESG commitments, and report on the progress we have made.
Our goal is clear – to ensure we never miss a patient dose, increase access through Biosimilars, and bring new and innovative medicines to healthcare systems.
100 days ago, I joined STADA Group, and I am hugely impressed by the dedication and passion this team brings to amplifying and accelerating our ability to serve patients, partner with pharmacists and physicians with innovative therapy options in neurology and nephrology. We have one of the broadest portfolios of EU-approved biosimilars, and specialty generics that delivers high quality products delivering much need savings to strained healthcare systems.
Our clear commitment to providing access to more patients in more countries – not least through close collaboration with our trusted partners – gives me great confidence that no patient will be left behind on access to the most appropriate treatments.
#OneSTADA #CaringForPeoplesHealth #Specialty